P783 Clinical, Humanistic, and Economic Burden in Patients with PNH Receiving C5 Inhibition Treatment across UK, Germany, and France. Insights from the Commodore Burden of Illness Study

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disorder. In the UK, Germany, and France, C5 complement inhibitors, such as eculizumab and ravulizumab, both of which are intravenously (IV) infused, are the standard of care for PNH